Bicara Therapeutics (BCAX) Cash from Operations (2023 - 2026)

Bicara Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 37508000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 33.45% year-over-year to 37508000.0; the TTM figure through Mar 2026 stood at 116236000.0 (down 31.68% YoY), while the FY2025 annual figure was 106834000.0, down 42.92% from the prior year.
• Cash from Operations for Q1 2026 stood at 37508000.0, down from 23886000.0 in the prior quarter.
• The five-year high for Cash from Operations was 8036000.0 in Q4 2023, with the low at 37508000.0 in Q1 2026.
• The 4-year median for Cash from Operations is 24740000.0 (2025), against an average of 22712900.0.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations plunged 273.72% in 2024, then climbed 20.46% in 2025.
• Bicara Therapeutics' Cash from Operations stood at 8036000.0 in 2023, then slumped by 273.72% to 30032000.0 in 2024, then advanced by 20.46% to 23886000.0 in 2025, then sank by 57.03% to 37508000.0 in 2026.
• Business Quant data shows BCAX's Cash from Operations at 37508000.0 in Q1 2026, 23886000.0 in Q4 2025, and 29248000.0 in Q3 2025.